Press Releases

SOUTH PLAINFIELD, N.J. , Dec. 19, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (Nasdaq: PTCT) today announced that both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have granted orphan-drug designation (ODD) to Translarna™ (ataluren) for the treatment of

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 (c) (4) SOUTH PLAINFIELD, N.J., Dec. 17, 2014 -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on December 15, 2014 it approved non-statutory stock options to purchase an aggregate of 46,750 shares of its common

-First drug for the underlying cause of nonsense mutation Duchenne muscular dystrophy -

SOUTH PLAINFIELD, N.J. , Nov. 21, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) is proud to announce that the 2014 Legend of Technology Award for Vision, Innovation, and Leadership has been awarded to Stuart W. Peltz , Ph.D., Chief Executive Officer.

- PTC Therapeutics to Receive $10 Million Milestone Payment from Roche -

SOUTH PLAINFIELD, N.J. , Nov. 17, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on November 14, 2014 it approved non-statutory stock options to purchase an aggregate of 92,000 shares of its common stock to fifteen new employees.

SOUTH PLAINFIELD, N.J. , Nov. 17, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointment of Tuyen Ong , M.D., MRCOphth, MBA, as Senior Vice President, Head of Clinical Development and Translational Research . Dr. Ong will be responsible for Clinical Development

SOUTH PLAINFIELD, N.J. , Nov. 14, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) received the Outstanding Innovation Award at The 2014 Rare & Orphan Advocacy & Research Awards for Translarna ™ , the first treatment approved in the European Union for Duchenne muscular dystrophy.

SOUTH PLAINFIELD, N.J. , Nov. 13, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it will hold its 2 nd Annual Science Day on Monday, November 24, 2014 from 8:00 a.m. to 12:00 p.m. ET at the Le Parker Meridien in New York City .

- Confirmatory Phase 3 ACT DMD clinical trial fully enrolled -
- Rolling NDA submission for Translarna in nmDMD planned before year end 2014 -
- European commercial launch activities well underway -
- Initiation of Phase 1b/2a trial for SMA program planned -
- IND application for PTC596 to be submitted before year end 2014 -
- Successful financing raised estimated net proceeds of $117.5 million -